The third quarter saw a raft of first-in-class approvals, including the first RNA interference (RNAi) drug, the first nanobody, and a novel immunotoxin combining a CD22 Fv antibody fragment and an exotoxin. RNAi, antisense and small molecules achieved clinical…

Fonte: VOLUME 36 NUMBER 12 DECEMBER 2018 NATURE BIOTECHNOLOGY

Para acessar a publicação na íntegra clique aqui